1.
Indian J Cancer
;
2012 Jul-Sept; 49(3): 260-265
Artigo
em Inglês
| IMSEAR
| ID: sea-144583
RESUMO
Janus Activated Kinase (JAK) 2 plays an important role in the pathogenesis of myelofibrosis (MF). Ruxolitinib (INCB018424, Jakafi) is a potent dual JAK1 and JAK2 inhibitor. In November 2011, it became approved by the US FDA for the treatment of intermediate or high-risk MF. This review shall outline the role of Ruxolitinib in the current management of MF and its potential future.